# A Case of Persistent KSHV Viremia in the Context of HIV, SARS-CoV-2, and Other Co-Infections

**Authors:** Humaira Lambarey, Melissa J. Blumenthal, Prishanta Chinna, Vincent N. Naude, Lauren Jennings, Catherine Orrell, Georgia Schäfer

PMC · DOI: 10.3390/tropicalmed10020053 · Tropical Medicine and Infectious Disease · 2025-02-10

## TL;DR

A man with HIV and other infections had persistent high KSHV virus levels, which could increase his risk for severe KSHV-related diseases.

## Contribution

This case study reports persistent lytic KSHV viremia in a PLWH patient co-infected with SARS-CoV-2 and tuberculosis.

## Key findings

- The patient had unusually high KSHV viral load before and after SARS-CoV-2 infection.
- Inflammatory markers CRP and IL-6 increased steadily during the 2-year follow-up.
- HIV viral load remained controlled, but CD4 count was near immunosuppression levels.

## Abstract

Despite the high prevalence of latent Kaposi’s sarcoma-associated herpesvirus (KSHV) infections in patients from endemic areas with a high human immunodeficiency virus (HIV) prevalence, KSHV lytic reactivation in the context of other co-infections is not well understood. Lytic KSHV infections can contribute to severe inflammatory symptoms and KSHV-associated pathogenesis. We have previously reported on KSHV reactivation upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure in a non-hospitalised cohort of people living with HIV (PLWH). From this cohort, we identified a 34-year-old male who presented for routine HIV care in May 2021 with an unusually high KSHV viral load (VL) of 189,946.3 copies/106 cells, before SARS-CoV-2 infection. The patient was invited into a 2-year follow-up study where his peripheral blood was analysed for selected virological, clinical, and inflammatory parameters every 6 months. He remained highly viremic for KSHV throughout the 2-year study period, during which he was infected with SARS-CoV-2 and developed disseminated tuberculosis, with steadily increasing levels of the inflammatory markers C-reactive protein (CRP), and interleukin-6 (IL-6). His HIV VL remained controlled (<1000 copies/mL) and his CD4 count bordered immunosuppression (±200 cells/µL), suggesting some responsiveness to antiretroviral treatment (ART). However, the patient’s uncontrolled lytic KSHV infection may increase his risk for developing a KSHV-associated pathology manifesting with inflammation which should be closely monitored beyond the study period.

## Linked entities

- **Proteins:** CRP (C-reactive protein), IL6 (interleukin 6)
- **Diseases:** Kaposi’s sarcoma (MONDO:0005055), SARS-CoV-2 (MONDO:0100096), tuberculosis (MONDO:0018076)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** Co-Infections (MESH:D060085), SARS-CoV-2 infection (MESH:D000086382), infected (MESH:D007239), inflammation (MESH:D007249), disseminated tuberculosis (MESH:D014376)
- **Species:** Human immunodeficiency virus (species) [taxon 12721], Homo sapiens (human, species) [taxon 9606], Human gammaherpesvirus 8 (no rank) [taxon 37296]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11860674/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11860674/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC11860674/full.md

---
Source: https://tomesphere.com/paper/PMC11860674